Mr Carlos Alberto Escobar, NP-C | |
6460 Highway 92, Ste 200, Acworth, GA 30102-2998 | |
(770) 880-4517 | |
Not Available |
Full Name | Mr Carlos Alberto Escobar |
---|---|
Gender | Male |
Speciality | Nurse Practitioner - Family |
Location | 6460 Highway 92, Acworth, Georgia |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1215079736 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208600000X | Surgery | RN225443 (Georgia) | Secondary |
363LF0000X | Nurse Practitioner - Family | RN225443 (Georgia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr Carlos Alberto Escobar, NP-C 6460 Highway 92, Ste 200, Acworth, GA 30102-2998 Ph: (770) 880-4517 | Mr Carlos Alberto Escobar, NP-C 6460 Highway 92, Ste 200, Acworth, GA 30102-2998 Ph: (770) 880-4517 |
News Archive
Acusphere, Inc. today announced that it had completed the Marketing Authorisation Application dossier for its lead product candidate, Imagify (Perflubutane Polymer Microspheres) for Injectable Suspension, and is now starting the process of filing the MAA dossier with the European Medicines Agency to support the regulatory review of Imagify in the European Union.
In an elaborate study, biologists of the University of Luxembourg have found out that small molecules named microRNAs are, against many hopes, not yet suitable for early diagnosis of skin cancer, as well as supposedly for other types of cancer, in blood samples. For the first time they analysed all microRNAs in the serum of healthy people and thus provided a first complete image of the human "miRNome" in blood samples, in reference to the better-known "genome".
Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced that it has entered into agreements with Quintiles Commercial US, Inc. and Integrated Commercialization Services, Inc. (ICS) to support the anticipated launch of EXPAREL, should it be approved by the Food and Drug Administration (FDA) later this year.
The latest generation of genomic tests for breast cancer can improve physicians' ability to diagnose the disease and more precisely tailor each patient's treatment, according to a study being presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). The study examined the first commercially available genomic tests to determine the molecular subtype of a breast cancer tumor.
Researchers studied the effects of a 12-week exercise regimen on 148 active-duty Air Force airmen, half of whom also received a twice-daily nutrient beverage that included protein; the omega-3 fatty acid, DHA; lutein; phospholipids.
› Verified 7 days ago